Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

EDITORIAL

Diagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.

BLOOD COMMENTARIES

HOW I TREAT SERIES

Acquired Hemolytic Anemia

Diagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.

Diagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.

Diagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.

Diagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss their approaches to the treatment of patients with 4 different classes of acquired hemolytic anemia.

CLINICAL TRIALS AND OBSERVATIONS

Blockade of programmed death 1 (PD-1) is now established as a standard treatment for relapsed Hodgkin lymphoma, and how this approach can be incorporated into first line therapies is an important question. Allen et al report an early-phase trial of single agent pembrolizumab for an initial 3 cycles followed by 4 to 6 cycles of chemotherapy. They demonstrate encouraging single-agent activity and excellent efficacy and tolerability for the sequential therapy in previously untreated patients with either unfavorable early-stage or advanced-stage disease.

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Congenital neutropenias (CNs) are characterized by defective neutrophil maturation caused by mutations in any one of more than 20 different genes, including the signal recognition particle 54 gene (SRP54). Schürch et al show that SRP54 mutations found in CN act in a dominant negative manner in zebrafish models, causing neutropenia due to impaired splicing of the transcription factor Xbox-binding protein 1 (XBP1).

LYMPHOID NEOPLASIA

T-cell/histiocyte-rich large B-cell lymphoma has a unique tumor microenvironment with an extensive infiltrate of T cells and histiocytes. Using multiparameter immunophenotyping studies with sophisticated spatial image analyses, Griffin and colleagues report that the unique cellular architecture of this lymphoma’s microenvironment appears to be an important contributor to immune escape of the lymphoma cells.

Andreas Agathangelidis,on behalf of ERIC, the European Research Initiative on CLL,Anastasia Chatzidimitriou,on behalf of ERIC, the European Research Initiative on CLL,Katerina Gemenetzi,on behalf of ERIC, the European Research Initiative on CLL,Veronique Giudicelli,on behalf of ERIC, the European Research Initiative on CLL,Maria Karypidou,on behalf of ERIC, the European Research Initiative on CLL,Karla Plevova,on behalf of ERIC, the European Research Initiative on CLL,Zadie Davis,on behalf of ERIC, the European Research Initiative on CLL,Xiao-Jie Yan,on behalf of ERIC, the European Research Initiative on CLL,Sabine Jeromin,on behalf of ERIC, the European Research Initiative on CLL,Christof Schneider,on behalf of ERIC, the European Research Initiative on CLL,Lone Bredo Pedersen,on behalf of ERIC, the European Research Initiative on CLL,Renee C. Tschumper,on behalf of ERIC, the European Research Initiative on CLL,Lesley-Ann Sutton,on behalf of ERIC, the European Research Initiative on CLL,Panagiotis Baliakas,on behalf of ERIC, the European Research Initiative on CLL,Lydia Scarfò,on behalf of ERIC, the European Research Initiative on CLL,Ellen J. van Gastel,on behalf of ERIC, the European Research Initiative on CLL,Marine Armand,on behalf of ERIC, the European Research Initiative on CLL,Eugen Tausch,on behalf of ERIC, the European Research Initiative on CLL,Bella Biderman,on behalf of ERIC, the European Research Initiative on CLL,Constance Baer,on behalf of ERIC, the European Research Initiative on CLL,Davide Bagnara,on behalf of ERIC, the European Research Initiative on CLL,Alba Navarro,on behalf of ERIC, the European Research Initiative on CLL,Anne Langlois de Septenville,on behalf of ERIC, the European Research Initiative on CLL,Valentina Guido,on behalf of ERIC, the European Research Initiative on CLL,Gerlinde Mitterbauer-Hohendanner,on behalf of ERIC, the European Research Initiative on CLL,Aleksandar Dimovski,on behalf of ERIC, the European Research Initiative on CLL,Christian Brieghel,on behalf of ERIC, the European Research Initiative on CLL,Sarah Lawless,on behalf of ERIC, the European Research Initiative on CLL,Manja Meggendorfer,on behalf of ERIC, the European Research Initiative on CLL,Kamila Brazdilova,on behalf of ERIC, the European Research Initiative on CLL,Matthias Ritgen,on behalf of ERIC, the European Research Initiative on CLL,Monica Facco,on behalf of ERIC, the European Research Initiative on CLL,Cristina Tresoldi,on behalf of ERIC, the European Research Initiative on CLL,Andrea Visentin,on behalf of ERIC, the European Research Initiative on CLL,Andrea Patriarca,on behalf of ERIC, the European Research Initiative on CLL,Mark Catherwood,on behalf of ERIC, the European Research Initiative on CLL,Lisa Bonello,on behalf of ERIC, the European Research Initiative on CLL,Andrey Sudarikov,on behalf of ERIC, the European Research Initiative on CLL,Katrina Vanura,on behalf of ERIC, the European Research Initiative on CLL,Maria Roumelioti,on behalf of ERIC, the European Research Initiative on CLL,Hana Skuhrova Francova,on behalf of ERIC, the European Research Initiative on CLL,Theodoros Moysiadis,on behalf of ERIC, the European Research Initiative on CLL,Silvio Veronese,on behalf of ERIC, the European Research Initiative on CLL,Krzysztof Giannopoulos,on behalf of ERIC, the European Research Initiative on CLL,Larry Mansouri,on behalf of ERIC, the European Research Initiative on CLL,Teodora Karan-Djurasevic,on behalf of ERIC, the European Research Initiative on CLL,Raphael Sandaltzopoulos,on behalf of ERIC, the European Research Initiative on CLL,Csaba Bödör,on behalf of ERIC, the European Research Initiative on CLL,Franco Fais,on behalf of ERIC, the European Research Initiative on CLL,Arnon Kater,on behalf of ERIC, the European Research Initiative on CLL,Irina Panovska,on behalf of ERIC, the European Research Initiative on CLL,Davide Rossi,on behalf of ERIC, the European Research Initiative on CLL,Salem Alshemmari,on behalf of ERIC, the European Research Initiative on CLL,Panagiotis Panagiotidis,on behalf of ERIC, the European Research Initiative on CLL,Paul Costeas,on behalf of ERIC, the European Research Initiative on CLL,Blanca Espinet,on behalf of ERIC, the European Research Initiative on CLL,Darko Antic,on behalf of ERIC, the European Research Initiative on CLL,Letizia Foroni,on behalf of ERIC, the European Research Initiative on CLL,Marco Montillo,on behalf of ERIC, the European Research Initiative on CLL,Livio Trentin,on behalf of ERIC, the European Research Initiative on CLL,Niki Stavroyianni,on behalf of ERIC, the European Research Initiative on CLL,Gianluca Gaidano,on behalf of ERIC, the European Research Initiative on CLL,Paola Francia di Celle,on behalf of ERIC, the European Research Initiative on CLL,Carsten Niemann,on behalf of ERIC, the European Research Initiative on CLL,Elias Campo,on behalf of ERIC, the European Research Initiative on CLL,Achilles Anagnostopoulos,on behalf of ERIC, the European Research Initiative on CLL,Christiane Pott,on behalf of ERIC, the European Research Initiative on CLL,Kirsten Fischer,on behalf of ERIC, the European Research Initiative on CLL,Michael Hallek,on behalf of ERIC, the European Research Initiative on CLL,David Oscier,on behalf of ERIC, the European Research Initiative on CLL,Stephan Stilgenbauer,on behalf of ERIC, the European Research Initiative on CLL,Claudia Haferlach,on behalf of ERIC, the European Research Initiative on CLL,Diane Jelinek,on behalf of ERIC, the European Research Initiative on CLL,Nicholas Chiorazzi,on behalf of ERIC, the European Research Initiative on CLL,Sarka Pospisilova,on behalf of ERIC, the European Research Initiative on CLL,Marie-Paule Lefranc,on behalf of ERIC, the European Research Initiative on CLL,Sofia Kossida,on behalf of ERIC, the European Research Initiative on CLL,Anton W. Langerak,on behalf of ERIC, the European Research Initiative on CLL,Chrysoula Belessi,on behalf of ERIC, the European Research Initiative on CLL,Frederic Davi,on behalf of ERIC, the European Research Initiative on CLL,Richard Rosenquist,on behalf of ERIC, the European Research Initiative on CLL,Paolo Ghia,on behalf of ERIC, the European Research Initiative on CLL,Kostas Stamatopoulos,on behalf of ERIC, the European Research Initiative on CLL

MYELOID NEOPLASIA

Xiao et al describe a subset of acute myeloid leukemias (AMLs) that displays expansion of mature plasmacytoid dendritic cells (pDCs). This subset is enriched for RUNX1 mutations and has a poor prognosis. The authors also show that AML blasts with RUNX1 mutations have a propensity to make pDCs, suggesting unappreciated leukemia biology and a possible therapeutic target for further exploration.

THROMBOSIS AND HEMOSTASIS

Plasma microvesicles are a heterogeneous collection of membranous cell-derived microparticles that are released in response to various insults and are typically prothrombotic. Obermayer and colleagues report the discovery of naturally occurring immunoglobulin M (IgM) antibodies that bind to microvesicles and inhibit their contribution to the propagation of coagulation. Their work reveals a specific endogenous means to counter the prothrombotic effect of microvesicles and an anticoagulant role for innate immunity.

TRANSPLANTATION

LETTERS TO BLOOD

BLOOD WORK

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals